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Pseudohypoaldosteronism type II (PHA II) is caused by
mutations of two members of WNK ((with no lysine (k))
kinase family. WNK4 wild type (WT) has been shown to
inhibit the activity and surface expression of sodium chloride
cotransporter (NCC) when expressed in Xenopus oocytes.
Here, we have studied NCC protein processing in mammalian
cells in the presence or absence of WNK4 WT and its mutants,
E562K and R1185C, by surface biotinylation, Western blot,
co-immunoprecipitation (Co-IP) and immunostaining. WNK4
WT significantly reduced NCC surface expression in Cos-7
cells (58.976.8% vs 100% in control, Po0.001, n¼ 6),
whereas its mutant E562K has no significant effect on NCC
surface expression (92.975.3% vs 100%, P¼NS, n¼ 6).
Another mutant R1185C still partially reduces surface
expression of NCC (76.2711.8% vs 100%, Po0.05, n¼ 6). The
reduction of NCC surface expression by WNK4 WT
(62.973.3% of control group) is not altered by WT dynamin
((61.873.7% (P¼NS)) or its mutant K44A ((65.4714.1%
(P¼NS)). A Co-IP study showed that both WNK4 WT and
WNK4 E562K interact with NCC. Furthermore, a proton pump
inhibitor, bafilomycin A1, partially reverses the inhibitory
effect of WNK4 WT on NCC expression. Our data suggest that
WNK4 WT significantly inhibits NCC surface expression, which
is not owing to an increase in clathrin-mediated endocytosis
of NCC, but likely results from enhanced degradation of NCC
through a lysosomal pathway.
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WNK (with no lysine (k)) kinase is a newly characterized
member of the subfamily of serine/threonine kinases.1
Mutations in two members of this family, WNK1 and
WNK4, result in pseudohypoaldosteronism type II (PHA
II),2 also referred to as Gordon syndrome or familial
hyperkalemia and hypertension. PHA II is a rare autosomal
dominant disorder characterized by hypertension, hyperka-
lemia, hyperchloremic metabolic acidosis, and normal
glomerular filtration rate. The clinical phenotype of PHA II
is opposite to that reported for Gitelman syndrome, a disease
caused by loss-of-function mutations in the thiazide-sensitive
sodium chloride cotransporter (NCC).3 Previous studies on
PHA II have shown that those clinical features are chloride
dependent4,5 and correctable by a thiazide diuretic, a specific
inhibitor of NCC, implicating a primary defect in sodium
chloride handling in the distal nephron. Studies have shown
that wild-type (WT) WNK4 inhibits sodium uptake by
reducing NCC surface expression in Xenopus oocytes.6,7 A
recent study further showed that the WNK4 carboxyl-
terminus mediates NCC suppression.8 However, the mole-
cular mechanism of how WNK kinases regulate NCC surface
expression remains to be clarified, especially in mammalian
cells. To this end, we report that WNK4 WT reduces NCC
surface expression, whereas the PHA II-causing mutants
either lose their ability entirely (WNK4 E562K) or partially
reduce NCC surface expression (WNK4 R1185C). Co-
expression of NCC with a dynamin 2 WT or its dominant-
negative mutant K44A does not alter the ability of WNK4
WT to reduce NCC surface expression. Our data also suggest
that the reduced NCC surface expression induced by WNK4
WT is likely owing to enhanced degradation of NCC through
the lysosomal pathway.
RESULTS
Effects of WNK4 and its mutants on NCC surface expression in
Cos-7 cells
Cos-7 cells were transiently transfected with green fluorescent
protein (GFP)-NCC either alone or in combination with
WNK4 WT or its mutants E562K or R1185C (Figure 1).
Immunostaining and confocal microscopy were subsequently
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performed to assess the distribution of NCC in Cos-7 cells.
As shown in Figure 2, the cells transfected with NCC alone,
the distribution of GFP-NCC (Figure 2a–c) was at the cell
membrane and within the cytoplasm. When cells were
cotransfected with WNK4 WT and GFP-NCC (Figure 2d–f),
NCC was now detected primarily within the cytoplasm and
notably the cell surface portion of NCC was reduced. In
contrast, when Cos-7 cells were cotransfected with WNK4
E562K and GFP-NCC (Figure 2g–i), NCC could again be
detected at the cell surface, similar to that observed in the
cells transfected with NCC alone. A similar effect on NCC
surface expression was also observed in the cells cotransfected
with WNK4 R1185C (Figure 2j–l). Similar expression
patterns of NCC, WNK4 WT, and its mutants were found
in each group when Cos-7 cells were transfected with HA-
NCC (data not shown), suggesting that the addition of a tag
to NCC would not impact NCC expression pattern. These
results suggested that WNK4 WT reduces NCC surface
expression, whereas PHA II-causing mutants do not affect
NCC surface expression.
Effects of WNK4 and its mutants on NCC expression in renal
epithelial cells
The effects of WNK4 WT and its mutants on NCC surface
expression were subsequently evaluated in renal epithelial M-1
cells. As shown in Figure 3, NCC was expressed both in the
apical membrane and cytoplasm in M-1 cells transfected with
GFP-NCC alone (Figure 3a). As observed in Cos7 cells,
surface NCC was reduced after cotransfection with GFP-NCC
and WNK4 WT (Figure 3b). However, NCC surface
expression was not affected in M-1 cells cotransfected with
NCC and WNK4 E562K (Figure 3c), suggesting that WNK4
E562K lacked an inhibitory effect on NCC surface expression.
Similarly, NCC surface expression was unaffected in M-1 cells
cotransfected with NCC and WNK4 R1185C (Figure 3d).
Effect of WNK4 on NCC surface expression quantified in Cos-7
cells
To confirm the above immunofluorescent results, surface
biotinylation experiments were performed to determine the
effect of WNK4 WT and its mutants on NCC surface
expression in Cos-7 cells. As shown in Figure 4, NCC surface
expression was reduced significantly (41.1%) in Cos-7 cells
cotransfected with WNK4 WT and NCC compared to the
cells cotransfected with NCC and a CD4 plasmid (control
group) (58.976.8% vs 100%, Po0.001, n¼ 6) (Figure 4b).
CD4, a membrane protein transcribed using the same
cytomegalovirus promoter, was employed to equalize the
amount of DNA in all experiments. There was no difference
in NCC surface expression between the cells transfected with
NCC alone and that cotransfected with NCC and CD4
plasmid (data not shown). In Cos-7 cells transfected with
NCC and WNK4 E562K, NCC surface expression was not
significantly diminished compared to control group
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Figure 1 | Wild-type human WNK4 and NCC and their predicted
domains and WNK4 mutant constructs. P, proline-rich regions; KD,
the kinase domain; AI, an autoinhibitory domain; Cc, a coiled-coil
domain; N, the amino-terminus; and C, the carboxyl-terminus. All
WNK4 constructs contain an myc tag at the N-terminus. WNK4 WT is a
wild-type WNK4 construct; WNK4 E562K is a WNK4 PHA II-causing
mutant with a point mutation in a highly conserved region just distal
to the first coiled-coil domain; and WNK4 R1185C is another WNK4
PHA II-causing mutant with a point mutation in the region just distal
to the second coiled-coil domain. All point mutations are indicated as
black line inserts. GFP-NCC is a human WT NCC construct with an
N-terminal GFP tag; HA-NCC is a human WT NCC construct with HA
tag at the N-terminus; and TM indicates the 12 transmembrane
domains of NCC.
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Figure 2 | WNK4 WT reduces, but PHA II-causing mutants do not
affect NCC surface expression in Cos-7 cells. Cos-7 cells were
transfected only with (a–c) GFP-NCC or doubly transfected with
(d–f) GFP-NCC and WNK4 WT or its disease mutants, (g–i) E562K or
(j–l) R1185C. Immunofluorescence and confocal microscopy were
performed in Cos-7 cells 48 h after transfection. (a–c) Cos-7 cells
were transfected with GFP-NCC as a control and NCC in (a) green is
seen both in plasma membrane and cytoplasm. (d–f) Cos-7 cells were
cotransfected with GFP-NCC and myc-tagged WNK4 WT. GFP-NCC in
(d) green, WNK4 WT stained in (e) red, and the (f) merge picture are
shown. NCC is distributed primarily in the cytoplasm and colocalized
with WNK4 in the perinuclear region. (g–i) Cos-7 cells were
cotransfected with GFP-NCC and myc-tagged WNK4 E562K. GFP-NCC
in (g) green, E562K stained in (h) red, and the (i) merge picture are
shown. (g) The surface expression of NCC is restored and its
cytoplasmic distribution is similar to WNK4 WT group. (j–l) Cos-7
cells were cotransfected GFP-NCC and myc-tagged WNK4 R1185C.
GFP-NCC again in (j) green, R1185C stained in (k) red, and the
(l) merge picture are shown. The expression patterns of NCC and
R1185C are similar to the E562K group.
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(92.975.3% vs 100%, P¼NS, n¼ 6) (Figure 4b), indicating
that WNK4 E562K lost its ability to reduce NCC surface
expression. To our surprise, another mutant, WNK4 R1185C,
could still reduce NCC surface expression albeit to a less
extent compared to control group (76.2711.8% vs 100%,
Po0.05, n¼ 6) (Figure 4b). In addition, WNK4 D321A
(dead kinase) had no effect on NCC surface expression,
suggesting that WNK4 to function properly requires intact
kinase activity (data not shown).
Effect of WNK4 on NCC surface expression is not affected by
dynamin
Dynamin 2 wild type (Dyn WT) controls the pinching of
clathrin-coated endocytic vesicles from the plasma mem-
brane and the budding of vesicles from the Golgi apparatus.9
A dominant-negative dynamin mutant K44A (Dyn K44A)
blocks clathrin-mediated endocytosis of many membrane
proteins10 and is also known to affect the integrity of the
Golgi in some cell types.11 To investigate whether the ability
of WNK4 WT to reduce NCC surface expression involves a
dynamin-mediated pathway, we quantified the NCC surface
expression by surface biotinylation in Cos-7 cells in the
presence or absence of Dyn WT or Dyn K44A. As shown in
Figure 5, Cos-7 cells were cotransfected with HA-NCC in
combination with either CD4 or WNK4 WT. NCC surface
expression was significantly reduced in WNK4 WT group
(62.973.3%, lane 4 vs 100% in CD4 control group, lane 1,
Po0.001, n¼ 4). When Cos-7 cells were cotransfected HA-
NCC with WNK4 WT and Dyn WT or its dominant-negative
mutant Dyn K44A, the reduction of NCC surface expression
was not further altered by Dyn WT (61.873.7%, P¼NS
compared to WNK4 group) or Dyn K44A (65.4714.1%,
P¼NS, compared to WNK4 group). These data suggest that
the reduction of NCC surface expression by WNK4 is
independent of the clathrin-mediated endocytosis pathway.
Dynamin 2 and its dominant-negative mutant K44A do not
affect the distribution of NCC in the presence or absence of
WNK4
NCC is expressed both at the plasma membrane and within
the cytoplasm in Cos-7 cells transiently transfected with HA-
NCC (Figure 6b). Dyn WT is expressed uniformly in Cos-7
cells (Figure 6a). Dyn K44A, on the other hand, has a distinct
NCC alone NCC+WNK4 WT
NCC+WNK4 E562K NCC+WNK4 R1185C
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Figure 3 | WNK4 reduces the surface expression of NCC in
polarized M-1 cells. M-1 cells were grown on TranswellTM cell culture
inserts and were transiently transfected with a GFP-tagged NCC alone
as a (a) control or in (b) combination with myc tagged WNK4 WT or
(c) PHA II-causing mutant WNK4 E562K or (d) WNK4 R1185C after the
cells reached 80–90% confluence. Immunostaining experiments were
performed 2 days after transfection and confocal microscopic images
of the cells were obtained. Mouse monoclonal anti-myc antibody and
rabbit anti-ZO-1 antibody were used for immunostaining studies. The
results of immunofluorescence and confocal microscopy are shown
in M-1 cells. All images were captured in an identical manner. The
image stacks at top were obtained at Z-axis and the image at the
bottom was captured at apical level as indicted using ZO-1, a tight
junction marker. ZO-1 stained in red, WNK4 stained in blue, and NCC
in green are shown as indicated. In (a), NCC (green) was localized to
both the apical membrane and cytoplasm. In (b), NCC appears to be
distributed in the subapical region and cytoplasm as seen in a Z-axis
view and the surface expression of NCC is reduced. In (c), NCC is
localized to both the apical membrane and cytoplasm, a distribution
similar to that in the (a) control, suggesting that surface expression of
NCC is restored in the presence of the PHAII-causing mutant, WNK4
E562K. In (d), the surface expression of NCC in the WNK4 R1185C
group is similar to the WNK4 E562K group, indicating that
PHAII-causing mutants lost their inhibitory effect on NCC
surface expression.
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Figure 4 | Quantitative analysis of the effect of WNK4 WT and its
mutants on surface expression of NCC in Cos-7 cells. Cos-7 cells
were cotransfected with NCC in combination with either CD4, or
WNK4 WT or WNK4 mutants as indicated. (a) The top panel is a
representative immunoblot measuring the surface biotinylated NCC.
Bottom panel represents protein loading control with b-actin. (b) The
data shown in the bar graph represent the combined results of
luminescent analysis of six independent experiments of surface
biotinylation studies. Biotinylated surface protein (NCC) and the
correspondent amount (total NCC) of total cell lysate were quantified
using Fujifilm LAS-1000. The fraction of cell surface NCC expression
over total NCC in the cell lysates was calculated and the values shown
reflect the relative percentage of that in NCCþCD4 (control group).
*Po0.001 in NCCþWT group vs NCCþCD4 group. #Po0.05 in
NCCþ R1185C group vs to NCCþCD4 group. NS indicates no
statistical difference of NCC surface expression in NCCþ E562K
group vs control group. The error bars are the s.d.
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punctate expression pattern (Figure 6c), consistent with a
previous report that this mutant blocks clathrin-mediated
endocytosis and is arrested at the clathrin-coated pits at the
plasma membrane.12 To further investigate whether Dyn WT
or Dyn K44A affects the localization of NCC in the presence
or absence of WNK4 WT, we conducted immunofluorescent
studies to examine the distribution of NCC in Cos-7 cells. As
shown in Figure 6, NCC retains a similar distribution in the
plasma membrane and cytoplasm in the cells cotransfected
with HA-NCC and Dyn WT (Figure 6e) or Dyn K44A
(Figure 6h) in the absence of WNK4 WT. Whereas in the cells
cotransfected with WNK4 WT and HA-NCC in combination
with either Dyn WT (Figure 6k) or Dyn K44A (Figure 6n),
NCC expression displayed a punctate pattern, primarily
distributed in the cytoplasm. These data again suggest that
WNK4 WT reduces NCC membrane expression and this
effect is not altered in the presence of either Dyn WT or its
dominant-negative mutant K44A.
WNK4 and its mutant E562K interact with NCC in Cos-7 cells
To elucidate whether the loss of function of the PHA II-
causing mutant, WNK4 E562K, is owing to a disruption of
the interaction between WNK4 and NCC, co-immunopreci-
pitation (Co-IP) experiments were performed in Cos-7 cells
transiently expressing NCC and either WNK4 WT or WNK4
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Figure 5 | The influence of WNK4 WT on NCC surface expression is
not altered by presence of dynamin WT or its dominant-negative
mutant K44A. (a) Cos-7 cells were cotransfected with (1) either HA-
tagged NCC and CD4 plasmid (as control), or (2) HA-tagged NCC and
WNK4 WT, in combination with either pEGFP vector or GFP-tagged
dynamin 2 wild-type (Dyn WT) or its dominant-negative mutant K44A
(Dyn K44A) as indicated. Forty-eight hours post-transfection, the cell
surface proteins were labeled with membrane-impermeable sulfo-
NHS-SS-biotin at 41C. The cell surface proteins were isolated by
NeutrAvidin beads, fractionated on SDS-polyacrylamide gel electro-
phoresis, and the surface portion of NCC was detected by Western
blotting using an NCC antibody as indicated. Total lysate dynamin
was detected by Western blotting using a GFP polyclonal antibody as
indicated. b-Actin is shown here as protein loading control. (b) The
data shown in the bar graph represent the combined results of
luminescent analysis of four independent experiments of surface
biotinylation studies. Biotinylated surface protein NCC and the
corresponding total NCC in cell lysate were quantified using Fujifilm
LAS-1000. The fraction of cell surface over total NCC expression in the
cell lysates was calculated and the values shown are the relative
percentage of that in CD4þVect group (control). *Po0.001 in
WNK4þVect group or WNK4þDyn WT or WNK4þ K44A group
compared to CD4þVect group, respectively. There is no statistical
difference between NCC surface expression in CD4þDyn WT or
CD4þ K44A group compared to CD4þVect group (control group) or
in WNK4þDyn WT or WNK4þ K44A group compared to
WNK4þVect group. The error bars are the s.d.
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Figure 6 | Dynamin WT or its dominant-negative mutant dose not
change NCC expression pattern. Cos-7 cells were (1) singly
transfected (top row) with (a) Dynamin 2 wild-type-GFP (Dyn WT),
(b) HA-NCC (NCC) or (c) Dynamin 2 K44A-GFP (Dyn K44A) or (2)
doubly transfected with either (d–f, second row) HA-NCC and
Dyn WT or (g–i, third row) HA-NCC and Dyn K44A or (3) triply
transfected with either (j–l, fourth row) HA-NCC, Dyn WT, and
myc-tagged WNK4 WT or (m–o, bottom row) HA-NCC, Dyn K44A, and
myc-tagged WNK4 WT. Immunofluorescence was performed 48 h
after transfection. HA-NCC was detected by a polyclonal antibody to
(red) HA epitope, myc-WNK4 WT was detected by a monoclonal
antibody against (blue) myc epitope and (green) Dyn WT and Dyn
K44A were visualized by green fluorescence on a confocal micro-
scope. Surface NCC expression is reduced in the presence of WNK4
WT, irrespective of presence of either Dyn WT or Dyn K44A. Scale
bar¼ 20 mm.
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E562K. As shown in Figure 7, vector alone (negative control)
could not pull down NCC (Figure 7b, lane 6). WNK4 WT co-
immunoprecipitated NCC (Figure 7b, lane 2) and so does its
mutant, WNK4 E562K (Figure 7b, lane 4). These results
demonstrated that WNK4 WT interacted with NCC and that
the disease mutant did not alter this interaction. This
excludes the possibility that loss of function of the WNK4
mutant was owing to altered protein–protein interaction.
Instead, it might be attributed to other mechanisms such as
alteration of phosphorylation of NCC that ultimately affects
NCC processing.
A role for lysosomal degradation in the regulation of NCC
surface expression by WNK4
To determine more closely how WNK4 affects NCC, we
investigated the effect of V-type proton pump inhibition on
NCC protein expression in Cos-7 cells. Bafilomycin A1 (Baf
A1) specifically inhibits the vacuolar-type Hþ -ATPase and
thereby affects acidic proteases by disturbing the pH of
endocytic organelles, including lysosomes.13 As shown in
Figure 8, when Cos-7 cells were cotransfected with NCC and
WNK4 WT, the steady-state protein expression of NCC was
significantly reduced in presence of WNK4 WT (63.773.1%
vs 10070% in NCCþCD4 control group, Po0.01, n¼ 3).
After Baf A1 treatment, the ability of WNK4 WT to reduce
the steady-state level of NCC was significantly diminished in
a dose-dependent manner (63.773.1% in non-Baf A1-
treated group vs 71.974.1% in 0.5 mM Baf A1-treated groups
and 63.773.1% in non-Baf A1-treated group vs 79.473.1%
in 1.0 mM Baf A1-treated group, Po0.05, n¼ 3) (Figure 8a).
As expected, the steady-state level of NCC surface expression
was not altered in the presence of the WNK4 E562K after Baf
A1 treatment (Figure 8b). Immunostaining further showed
that NCC, WNK4, and its mutant E562K colocalize with
cathepsin D, a lysosomal marker (Figure 9). These results
suggest that one of the mechanisms of action of WNK4 WT is
to promote the degradation of NCC via a lysosome-mediated
pathway. The observation that WNK4’s ability to reduce
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Figure 7 | Co-IP showed an interaction between WNK4 WT or its
mutant WNK4 E562K and NCC. Cos-7 cells were cotransfected with
GFP-NCC in combination with either myc-tagged WNK4 WT (lanes 1
and 2) or PHA II-causing mutant, WNK4 E562K (lanes 3 and 4) or
vector (lanes 5 and 6). The cells were lysed in lysis buffer and lysates
for Co-IP were incubated with mouse monoclonal anti-myc antibody
overnight, followed by protein A–agarose beads for 2 h at 41C. After
washing with phosphate-buffered saline, beads were eluted with SDS
Laemmli buffer (Bio-Rad Laboratories, Hercules, CA, USA) and the
eluted proteins were separated by SDS-polyacrylamide gel electro-
phoresis, blotted, and probed with an anti-GFP antibody. After
stripping, the membrane was blotted and probed with an anti-myc
antibody in immunoprecipitation (IP) experiments. (a) IP experiments:
Anti-myc antibody was used for precipitating WNK4 as well as
probing. Lane 1, lysate protein input; lane 2, IP for the WNK4 WT
group; lanes 3 and 4, lysate protein input and IP, respectively, for the
WNK4 E562K group; lanes 5 and 6, lysate protein input and IP,
respectively, for the vector group (negative control). As shown in
(a) anti-myc antibody immunoprecipitates both WNK4 WT and its
mutant, E562K. (b) Co-IP experiment: Anti-myc antibody was
used for precipitating NCC and the anti-GFP antibody was
used for probing. The lanes were indicated as in (a). As seen in (b),
NCC cannot be co-immunoprecipitated in the vector group lacking
WNK4 expression. However, NCC can be immunoprecipitated by
both WNK4 WT and the PHA II-causing mutant, WNK4 E562K,
suggesting that (1) WNK4 interacts with NCC either directly or
indirectly and (2) WNK4 E562K does not alter this interaction.
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Figure 8 | The role of WNK4 on NCC surface expression is owing
to enhanced degradation of NCC via a lysosomal pathway in Cos-
7 Cells. One day after transfection of the GFP-NCC with CD4 (control)
or WNK4 as indicated, Cos-7 cells were treated with 0.5 and 1.0mM of
the V-type proton pump inhibitor Baf A1 for 16 h at 371C. Lysates
were subjected to 5% SDS-polyacrylamide gel electrophoresis
followed by immunoblotting with rabbit anti-GFP and mouse anti
b-actin antibodies. Protein expression change was quantified after
the Baf A1 treatment. Plots are presented as the ratio change from
non-treated cells from control group (CD4). In (a), the top band
indicates a representative Western blot showing steady-state protein
level of NCC in the presence or absence of WNK4 WT after Baf A1
treatment. b-Actin indicates protein loading control, suggesting that
Baf A1 treatment does not affect actin expression level. The
histogram at bottom represents a summary result of three
independent experiments. In (b), top two bands indicate a
representative Western blot. The graph at the vbottom represents a
summary result of three independent experiments. Note that steady-
state amount of NCC in the presence of WNK4 WT was increased in a
dose-dependent manner after Baf A1 treatment, whereas NCC
expression in the presence of WNK4 mutant E562K was not
significantly changed, suggesting that the inhibitory effect of WNK4
WT on NCC surface expression is at least partially owing to increase of
degradation of NCC via lysosomal pathway. #Po0.01 compared to
control group (NCCþCD4). *Po0.05 compared to the group of
NCCþWNK WT without Baf A1 treatment.
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NCC surface expression is not altered in the presence of
dominant-negative dynamin mutant K44A (Figure 5) sup-
ports the conclusion that WNK4 promotes the direct
degradation of NCC via the lysosome without it first
translocating to the plasma membrane.
DISCUSSION
The kinase, WNK4, plays an important role in renal function
by regulating the activity of several renal transporters and ion
channels including NCC,6,7 the outer medullary potassium
ion channel (ROMK),14 the Naþ–Kþ–2Cl– cotransporter
(NKCC1)15 and the Cl/base exchanger SLC26A6 (CFEX).15
WNK4 is also known to regulate paracellular chloride ion
flux.16 In this paper, we report that WNK4 WT reduces the
surface expression of NCC in mammalian cells, especially in
renal epithelial cells. The data are consistent with experi-
ments published by others using the Xenopus oocyte
heterologous expression system.6,7 Furthermore, we show
that the reduction of NCC surface expression by WNK4 WT
is not affected by the presence of a dominant-negative
dynamin mutant but is affected by Baf A1, suggesting that
one mechanism of action of WNK4 is to enhance degrada-
tion of NCC through a lysosome-mediated pathway without
NCC first transiting to the plasma membrane.
The PHAII-causing mutants, E562K and R1185C, either
lose their functional effect totally or retain a partial ability to
reduce NCC surface expression. Again to take this further, we
showed that both WT and the WNK4 mutant E562K bind to
NCC. Experiments using only the C-terminal region of NCC7
showed that WNK4 interacts with the C-terminus of NCC, a
location in NCC known to play an essential role in the
regulation of its protein processing17,18 and function.19,20 A
recent study also showed that C-terminus of WNK4 is
responsible for its interaction with NCC.8 Our observation
that the WNK4 mutant E562K still binds to NCC
demonstrates that the functional differences among WT
and the PHAII-causing mutants are not owing to altered
protein–protein interactions between WNK4 mutant and
NCC.
NCC function is known to be regulated by deamino-Cys-
D-Arg-vasopression,21 aldosterone,22 estradiol,23 loop diure-
tics,24 or low sodium diet,25 and is decreased by chronic
hypokalemia.26 Structural analysis of NCC suggests that NCC
contains putative protein kinase A and protein kinase C
sites.27 Activation of protein kinase C with a phorbol ester
results in significant reduction of NCC function.27 However,
no effect of cAMP, cGMP, or 3-isobutyl-1-methylxanthine, an
activator of protein kinase A, on NCC function was
observed.27 Our observation that the WNK4 D321A (dead
kinase mutant) cannot reduce NCC surface expression was
also confirmed by others in oocytes.7 This finding is further
consistent with the notion that the kinase domain of WNK4
plays a role in the regulation of NCC function and
processing. One might speculate that WNK4 regulates NCC
function through a phosphorylation-dependent mechanism.
However, a recent study showed that C-terminus of WNK4
without kinase domain remained interaction with NCC and
was still able to inhibit NCC function,8 which is inconsistent
with our and others observations.7 Whether WNK4 regulates
NCC function through its phosphorylation of NCC remains
to be established.
Our observation that the PHAII-causing mutant, E562K,
does not decrease NCC surface expression is also consistent
with experiments published by other using the Xenopus
oocyte expression system.6,7 Interestingly, a mutation in
WNK1, another member of WNK kinase family, also causes
PHA II as result of the overexpression of WNK1 mRNA.2
WNK1 was shown to prevent WNK4 from reducing NCC
activity and surface expression in Xenopus oocytes.6 It has
been shown that WNK1 inhibition requires an intact WNK4
kinase domain, the region that binds to WNK1. WNK1
inhibition of WNK4 is dependent on WNK1 catalytic activity
and an intact WNK1 protein.8 These findings suggest that
WNK4 is a downstream target of WNK1 kinase and an intact
kinase domain of WNK4 remains critical in the regulation of
NCC function and NCC trafficking as well. Whether WNK4
possesses kinase activity and directly or indirectly phosphor-
ylates downstream targets such as NCC is still unclear.
NCC function, like other membrane transporters or
channels, could be regulated by several possible mechanisms
through its transport pathway. Reduction or abolishment of
NCC transporter activity might be owing to its impaired
protein synthesis, impaired protein processing, decreased
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Figure 9 | WNK4 WT or its mutant E562K and NCC colocalize with
cathepsin D, a lysosomal marker. Cos-7 cells were transfected with
either (a–c) GFP-NCC or (d–f) WNK4 WT or its disease mutant,
(g–i) E562K. Immunofluorescence experiments were performed 48 h
after transfection. (a) GFP-NCC was visualized by green fluorescence.
(d) Myc-WNK4 WT and its mutant (g) E562K were detected by a
monoclonal antibody against myc epitope followed by (green)
fluorescein isothiocyanate-labeled goat anti-mouse immunoglobulin
(Ig) G. The endogenous cathepsin D, (b, e, and h) a lysosomal marker
was detected by a polyclonal antibody followed by (red) Cy-3-labeled
goat anti-rabbit IgG. (c, f, and i) The merged pictures were shown for
the respective row in the third columns. This finding showed that
WNK4 or its mutant E562K and GFP-NCC colocalize with cathepsin D,
(in yellow) a lysosomal marker, suggesting that WNK4 directs mature
NCC into a lysosomal pathway for degradation. Scale bar¼ 20mm.
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insertion of an otherwise functional protein into the plasma
membrane, impaired functional properties of the cotran-
sporter, or accelerated protein removal or degradation.
WNK4 WT has been shown to inhibit NCC activity and
surface expression in Xenopus oocytes.6,7 We also showed that
WNK4 WT inhibits NCC surface expression in mammalian
cells, whereas the WNK4 mutant E562K loses its inhibitory
effect. We further showed that reduction of NCC surface
expression by WNK4 WT was not altered by the dominant-
negative dynamin mutant K44A, indicating that the inhibi-
tory effect of WNK4 WT on NCC surface expression is not
owing to an increase in a clathrin-mediated endocytic
pathway. A novel finding to our study is that steady-state
protein levels of NCC are reduced in the presence of WNK4
WT, but not its PHA II-causing mutant E562K, and the
reduction of NCC expression is partially reversed after
treatment with V-type proton pump, Baf A1, indicating that
WNK4 WT facilitates NCC degradation through a lysosome-
mediated pathway, which results in decreased insertion of
NCC into the plasma membrane. These findings demonstrate
that reduction of NCC surface expression by WNK4 WT is
partially attributed to enhanced degradation of NCC through
a lysosomal pathway, which provides insight into the
molecular mechanism underlying PHA II. However, these
data could not exclude the possibility that WNK4 may also
change overall NCC degradation, which ultimately affects
NCC surface expression. Other potential mechanisms of how
WNK4 regulates NCC function and trafficking remains to be
established.
Another important finding to this study is that the PHAII-
causing mutant, R1185C, retains partial function while still
reducing NCC surface expression, but the reduction is less
than WT. The differing effects of WNK4 mutants, E562K and
R1185C, on NCC surface expression could explain why the
clinical phenotypes are different among the PHA II-affected
families with these two different mutations. In the WNK4
E562K-affected family members, hypertension usually occurs
at an early age of their lives and hyperkalemia is also
present,28,29 whereas in the WNK4 R1185C-affected family,
the affected members usually present with hyperkalemia
associated with hyperchloremic acidosis and normal blood
pressure.30 The relatively mild phenotype is certainly
consistent with our observation that the R1185C retains a
partial effect on NCC surface expression. NCC is predomi-
nantly expressed in the distal convoluted tubule and is
responsible for 5% of the sodium reabsorption in the
kidney.31,32 Current available data support the notion that
WNK4 WT has a basal inhibitory effect on NCC activity and
surface expression preventing sodium retention. On the other
hand, the WNK4 mutant E562K is ineffective, ultimately
leading to enhanced NCC activity and sodium reabsorption
in distal nephron. The net result is hypertension consistent
with Gordon’s hypothesis that is intended to explain the
pathogenesis underlying PHAII.33 In the WNK4 R1185C-
affected patients, blood pressure is usually normal as this
mutant retains partial inhibitory effect on NCC.
Importantly, the mutation, E562K, is located in the highly
conserved region just distal to the first coiled-coil domain,
whereas the mutation, R1185C, resides in the conserved
region just distal to the second coiled-coil domain.2 The
demonstration of the differing impact of these two missense
mutations on WNK4 function and ultimate disease severity is
the first step in understanding the functional importance of
the individual domains of WNK4.
MATERIALS AND METHODS
Plasmids and constructs
Human WT WNK4 was amplified by polymerase chain reaction
technique using a human kidney cDNA library and expressed
sequence tag clone from Incyte Corporation (Wilmington, DE,
USA) as template. The polymerase chain reaction product matched
the human WNK4 sequence (GenBank Accession no.: AF390018).
The N-terminal myc-tagged WNK4 WT construct was generated by
subcloning the WNK4 cDNA into pCMV-taq 3B vector (Stratagene,
La Jolla, CA, USA). WNK4 disease mutants, E562K and R1185C,
were generated using Quickchange site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA). Human WT NCC (GenBank
Accession no.: NM_000339) was also amplified from a human
kidney cDNA library using polymerase chain reaction technique and
subcloned into pEGFP-C1 (Clontech, Palo Alto, CA, USA) and
pcDNA 3.1 (Invitrogen, Carlsbad, CA, USA) vectors. Thus, the
N-terminal GFP- and HA-tagged NCC constructs were generated.
All constructs as shown in Figure 1 were confirmed by DNA
sequencing. Dynamin 2 (aa) constructs (Dyn2-GFP (WT) and
Dyn2K44A-GFP) were the gift of Dr MA McNiven (Mayo Clinic,
Rochester, MN, USA).
Cell culture and transfection
Cos-7 and M-1 cells obtained from American Type Tissue Culture
(ATCC) (Manassas, VA, USA) were maintained in Dulbecco’s
modified Eagle’s medium (Cos-7) or Dulbecco’s modified Eagle’s
medium/F12 (M-1) medium with L-glutamine (2 mM), penicillin
(100 U/ml), streptomycin (100 mg/ml), and 10% fetal calf serum
and 0.005 M dexamethasone (M-1 only). LipofectAMINE 2000
(Invitrogen) was used for transfection according to the manufac-
turer’s instructions. Forty-eight hours after transfection, cells were
used for Western blot, immunostaining, and surface biotinylation.
Antibodies and immunofluorescent staining
The monoclonal antibody (9E10) for myc was obtained from Zymed
Laboratories (South San Francisco, CA, USA). The polyclonal
antibody for GFP was purchased from Clontech. The rabbit anti-
NCC antibody was a gift from Dr Mark Knepper (NIH/NHLBI,
Bethesda, MD, USA). The polyclonal antibody against cathepsin D
was obtained from Upstate (Charlottesville, VA, USA). For
immunostaining, the fixed cells were blocked with 5% normal
donkey serum in phosphate-buffered saline for 1 h. The cells were
then incubated with the primary antibody for 1 h, followed by the
appropriate secondary antibody conjugated to fluorescein isothio-
cyanate, Cy 3, or Cy 5 fluorescent dye (Jackson ImmunoResearch
Lab, West Grove, PA, USA) for 1 h. No antibodies from the same
species were used in any of the double-stained specimens. After
staining, the coverslips (for Cos-7) or transwells (for M-1) were
washed, mounted with antiquenching medium (Vector Lab,
Burlingame, CA, USA), and the slides were sealed.
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Western blotting analysis
Cells were harvested and processed as described previously.34. Briefly
after transfection, cells were lysed in lysis buffer containing 20 mM
Hepes, pH 7.5, 120 mM NaCl, 5.0 mM ethylenediamine tetraacetic
acid, 1.0% Triton X-100, 0.5 mM dithiothreitol, and the complete
protease inhibitor (Roche Diagnotics, Mannheim, Germany). The
lysates were spun at 6000 g for 5 min and the proteins from
supernatant were quantified by BCA Protein Assay kit (Pierce,
Rockford, IL, USA). The protein sample was then separated by SDS-
polyacrylamide gel electrophoresis. After transferring, the mem-
brane was probed with specific antibodies and detected using ECL
plus system (Amersham Biosciences Corp., Piscataway, NJ, USA) or
Super signal (Pierce) as described previously.35
Confocal laser microscopy
The fluorescence label was examined with UltraView confocal
imaging system (Perkin-Elmer Life Sciences, Boston, MA, USA).
Images were acquired using the manufacturer’s software. To obtain
three-dimensional images, each XY plane of the sample with a depth
of 0.4 mm in Z-direction was scanned by the confocal laser, and the
picture serials along the Z-axis were combined, reconstructed, and
presented as XZ and YZ cross-section images using the Velocity
software (Improvision Ltd., Lexington, MA, USA). Images were
prepared for publication with Adobe Photoshop.
Surface biotinylation
Biotinylated NCC at the plasma membrane was precipitated as
described previously with some modifications.34 Lysates were
incubated with immobilized NeutrAvidin beads (Pierce) overnight
at 41C, and bound proteins were eluted with 2 Laemmli sample
buffer supplemented with 100mM dithiothreitol at 421C for 30 min.
The eluted proteins were subjected to SDS-polyacrylamide gel
electrophoresis and Western blot. GFP-NCC was detected with GFP
antibody (1:3000).
Statistical analysis
The data are presented as the means7s.e. Statistical significance was
determined by Student’s t-test and analysis of variance. We assigned
significance at Po0.05.
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